Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China.
The First Affiliated Hospital of Zhejiang Chinese Medical University, NO. 54 Youdian Road, Hangzhou, Zhejiang, 310006, China.
J Ethnopharmacol. 2024 Jan 30;319(Pt 3):117322. doi: 10.1016/j.jep.2023.117322. Epub 2023 Oct 20.
With the emergence of endocrine resistance, the survival and good prognosis of HR-positive breast cancer (HR + BC) patients are threatened. As a common complementary and alternative therapy in cancer treatment, traditional Chinese medicine (TCM) has been widely used, and its internal mechanisms have been increasingly explored.
In this review, the development status and achievements in understanding of the mechanisms related to the anti-invasion and anti-metastasis effects of TCM against HR + BC and the reversal of endocrine drug resistance by TCM in recent years have been summarized to provide ideas for antitumour research on the active components of TCM/natural medicine.
We searched the electronic databases PubMed, Web of Science, and China National Knowledge Infrastructure database (CNKI) (from inception to July 2023) with the key words "HR-positive breast cancer" or "HR-positive breast carcinoma", "HR + BC" and "traditional Chinese medicine", "TCM", or "natural plant", "herb", etc., with the aim of elucidating the intrinsic mechanisms of traditional Chinese medicine and natural medicine in the treatment of HR + BC.
TCM/natural medicine monomers and formulas can regulate the expression of related genes and proteins through the PI3K/AKT, JAK2/STAT3, MAPK, Wnt and other signalling pathways, inhibit the proliferation and metastasis of HR + BC tumours, play a synergistic role in combination with endocrine drugs, and reverse endocrine drug resistance.
The wide variety of TCM/natural medicine components makes the research and development of new methods of TCM for BC treatments more selective and innovative. Although progress has been made on research on TCM/natural medicine, there are still many problems in clinical and basic experimental designs, and more in-depth scientific explorations and research are still needed.
随着内分泌耐药的出现，HR 阳性乳腺癌（HR+BC）患者的生存和预后良好受到威胁。作为癌症治疗中常见的补充和替代疗法，中药（TCM）已被广泛应用，其内在机制也在不断被探索。
本综述总结了近年来 TCM 抗 HR+BC 侵袭转移作用及逆转 TCM 内分泌耐药相关机制的研究进展和成果，为中药/天然药物活性成分抗肿瘤研究提供思路。
我们检索了电子数据库 PubMed、Web of Science 和中国知网（CNKI）（从创建到 2023 年 7 月），使用关键词“HR 阳性乳腺癌”或“HR 阳性乳腺癌”、“HR+BC”和“中药”、“TCM”或“天然植物”、“草药”等，旨在阐明中药和天然药物治疗 HR+BC 的内在机制。
TCM/天然药物单体和方剂可通过 PI3K/AKT、JAK2/STAT3、MAPK、Wnt 等信号通路调节相关基因和蛋白的表达，抑制 HR+BC 肿瘤的增殖和转移，与内分泌药物发挥协同作用，逆转内分泌耐药。
TCM/天然药物成分的多样性使 BC 治疗的 TCM 新方法的研究和开发更具选择性和创新性。尽管在中药/天然药物研究方面取得了进展，但在临床和基础实验设计方面仍存在许多问题，需要进行更深入的科学探索和研究。
